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A sensitive and specific non-sputum-based test would represent a game-changer for the diagnosis of 
childhood tuberculosis (TB). We assessed the diagnostic accuracy of the Fujifilm SILVAMP TB 
LAM (FujiLAM) and Alere Determine TB LAM Ag (AlereLAM) assays side by side for the detection 
of childhood TB. 
Methods  
In this cross-sectional study, we tested urine samples from children aged <15 years with presumed 
pulmonary TB. Children were consecutively recruited at the study sites in The Gambia, Mali, Nigeria 
and Tanzania from July 2017 to December 2018. Bio-banked urine samples were thawed and tested 
using FujiLAM and AlereLAM assays. We measured diagnostic performance against a 
microbiological reference standard (confirmed TB) and a composite reference standard (confirmed 
and unconfirmed TB). Sensitivity and specificity were estimated by performing bivariate random 
effects meta-analyses. 
Findings  
We included urine samples from 415 children; 63 (15%) had confirmed tuberculosis, 113 (27%) had 
unconfirmed tuberculosis, and 239 (58%) were unlikely tuberculosis. The HIV prevalence was 14·7% 
(61 of 415). Using the microbiological reference standard, the sensitivity of FujiLAM was 64·9% 
(95% CI 43·7-85·2; 40 of 63) compared with 30·7% (8·6-61·6; 19 of 63) for AlereLAM. The 
specificity of FujiLAM was 83·8% (76·5-89·4; 297 of 352) and 87·8% (79·0-93·7; 312 of 352) for 
AlereLAM. Against the composite reference standard, both assays had lower sensitivity, 32·9% 
(24·6-41·9; 58 of 176) for FujiLAM vs 20·2% (12·3-29·4; 36 of 176) for AlereLAM. Specificity of 
FujiLAM (83·3% [71·8-91·7]; 202 of 239) was comparable to AlereLAM (90·0% [81·6-95·6]; 216 of 
239). 
Interpretation  
In comparison to AlereLAM, FujiLAM demonstrated a higher sensitivity with comparable specificity, 
and could potentially add value to the rapid diagnosis of TB in children. 
Funding  
German Federal Ministry of Education and Research through KfW, Global Health Innovative 
Technology Fund and UKRI-GCRF and MRC program grant award.  
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Research in context 
Evidence before this study 
We searched PubMed Central for all studies or reports of lipoarabinomannan for the diagnosis of 
pulmonary tuberculosis in children. We used search terms “pulmonary tuberculosis” OR “ptb” 
AND “child” OR “infant” OR “adolescent” AND “lipoarabinomannan” OR “lam” AND “urine”, 
up to Mar 9, 2020. No language restrictions were applied. Our search returned five relevant 
publications that included children below 15 years undergoing LAM testing of urine for diagnosis 
of pulmonary tuberculous using AlereLAM. None of the studies used FujiLAM. The sensitivity of 
LAM, compared with confirmed TB, ranged from 48·3% to 73·2% for all children. Even though 
the WHO has recommended the use of AlereLAM to aid in the diagnosis of TB in children and 
adolescents with HIV, the test still shows sub-optimal sensitivity in most studies.  
When we searched using the search terms “fuji silvamp tb” OR “fujilam” OR “fuji silvamp tb lam”, 
we found two relevant studies, both of which were performed in adults with HIV and found that 
FujiLAM had a notably higher sensitivity than AlereLAM. No comparison of the two tests in 
children has been done to date, and the role of FujiLAM in childhood PTB diagnosis remains 
unknown. 
Added value of this study 
To our knowledge, this study is the first side-by-side comparison of FujiLAM and AlereLAM on 
samples of children from four countries. In our study, we compared the diagnostic performance of 
both tests. We showed the sensitivity of FujiLAM to be substantially higher than that of AlereLAM 
in all children, and in all sub-groups, relative to both microbiological and composite reference 
standards for tuberculosis. The high sensitivity of FujiLAM, however, was mainly observed in 
children with confirmed TB, and remains suboptimal. FujiLAM and AlereLAM had similar 
specificity. 
Implications of the available evidence 
FujiLAM showed substantially higher sensitivity compared with AlereLAM for the diagnosis of 
pulmonary tuberculosis in children, while maintaining comparable specificity. FujiLAM's 
sensitivity (64·9%) remains too low to be used as a rule-out test for childhood pulmonary 







Childhood tuberculosis (TB) is estimated to account for about 11% of the 10 million new cases of TB 
worldwide, and 15% of associated total mortality.1,2 However, these figures are likely to 
underestimate the true burden of the disease due to difficulty in obtaining good quality sputum 
samples from young children and the sub-optimal sensitivity of currently available routine diagnostic 
tools in children.3–5 Even when the sputum is successfully collected, traditional diagnostic methods 
such as culture or smear microscopy have low sensitivity in children due to the paucibacillary nature 
of the disease.6 Therefore, confirming the diagnosis of tuberculosis in children remains a challenge, 
with a majority of the diagnoses being made based on clinical criteria.4 
In recognition of these challenges, the World Health Organisation (WHO) has prioritised the need for 
rapid, point-of-care diagnostic solutions for detection of childhood TB.7 This new tool should ideally 
be non-sputum based, and be able to identify Mycobacterium tuberculosis (Mtb) with high sensitivity 
and specificity regardless of age, nutritional status or HIV status.8,9 The WHO has recommended the 
use of the urine-based point-of-care test Alere Determine LAM (‘AlereLAM’; Abbott, Palatine, IL, 
USA), to assist in the diagnosis of TB in children and adolescents with HIV.10 However, AlereLAM 
has demonstrated sub-optimal sensitivity in studies in children and therefore warrants the need for a 
more sensitive point-of-care test.11,12  
A novel test, Fujifilm SILVAMP TB LAM assay (‘FujiLAM’; Fujifilm, Tokyo, Japan), which has 
emerged is, similar to AlereLAM, based on the detection of mycobacterial lipoarabinomannan (LAM) 
antigen in urine.10 The FujiLAM is a new urine-based test for TB, that is based on the use of Silver 
Amplification Immunochromatography on a lateral flow strip which enables a 30-fold lower 
analytical sensitivity compared to the only commercially available LAM test, the  AlereLAM. Broger 
and colleagues reported a significantly higher diagnostic sensitivity when FujiLAM was compared 
with AlereLAM among in-patient adults with HIV.13 Given the significantly higher clinical sensitivity 
in adults, FujiLAM might also perform well in children, but to date, there are no published results. 
In this study, we set out to assess the diagnostic accuracy of FujiLAM for the detection of active 
pulmonary tuberculosis (PTB) compared side-by-side with AlereLAM in a centralised laboratory 
environment using previously collected, frozen urine samples from a cohort of children under the age 
of 15 years. 
Methods 
Study participants, setting, study design 
Children aged below 15 years with presumed PTB were consecutively enrolled at dedicated out-
patient childhood TB clinics at four sites in The Gambia, Mali, Nigeria, and, Tanzania from July 2017 
to December 2018 (detail on cohorts available in the Appendix, page 2). Children were eligible for 
enrolment if they had symptoms suggestive of PTB characterised by persistent or unremitting cough 
for more than two weeks with any of weight loss/failure to thrive, and persistent unexplained fever.14 
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No child was included in the study based on the presence of mediastinal lymphadenopathy alone. At 
enrolment, medical history and demographic information were obtained for each child. The 
anthropometric measurements, which included weight-for-age, length/height-for-age, and body mass 
index-for-age Z-scores were calculated using WHO 2007 reference standards.15 Clinical investigation 
included chest radiography and HIV testing in children whose HIV status was not known (HIV rapid 
test followed by a confirmatory PCR for children below 18 months, or HIV ELISA for children aged 
18 months or older). Each child then provided a urine specimen for LAM testing on a future date. 
This study is reported in accordance with the Standards for Reporting of Diagnostic Accuracy Studies 
guidelines.16 All samples were obtained using a well-defined protocol that received approval from the 
Gambia Government/MRC Joint Ethics Committee and from the IRB/IEC at the respective 
institutions where the samples were obtained. Written informed consent was obtained from the parent 
or legal guardian of each patient, and assent was obtained from the older children. Legal 
representatives of the participants were informed that all specimens collected would be used for TB 
diagnostic studies, and those who were willing to have specimens stored were asked to provide 
written informed consent specifically for these activities. 
Procedures 
Sputum samples were obtained from participants spontaneously or by sputum induction using 
nebulised hypertonic saline. For reference standard testing, the specimens were processed using 
standardised protocols at each study site. Reference standard testing was done on all available sputum 
specimens and included Xpert MTB/RIF Ultra assay (‘Xpert Ultra’; Cepheid, Sunnyvale, USA), 
mycobacteria growth indicator tube liquid culture (Becton Dickinson, Franklin Lakes, NJ, USA) and 
solid culture on Löwenstein-Jensen medium. The presence of Mtb in positive cultures was confirmed 
with acid-fast staining and MPT64 antigen detection (Abbott, Palatine, IL, USA) or MTBDRplus line 
probe assays (Hain Lifesciences, Nehren, Germany). For all sites except Nigeria, the microbiological 
reference standard used for the diagnosis of tuberculosis was a mycobacterial confirmation by Xpert 
Ultra or culture from at least one respiratory specimen. For Nigeria, Xpert Ultra alone was used as 
culture facilities were not available. The patients were categorised as having Confirmed TB, 
Unconfirmed TB or Unlikely TB by experienced clinicians at each study site using a combination of 
clinical and laboratory findings based on the revised classification (Table 1).14 Details of the reference 
standard outcomes among the diagnostic categories is available in the Appendix, page 3. 
At enrolment, spontaneously voided urine specimens were collected into a sterile container for the 
older children, and into a urine bag for the younger children. All urine specimens were stored 
immediately after collection until used for analysis. The duration of biobanking of the urine samples 
was between two and 19 months at minus 80oC in temperature-monitored freezers before the urine 
LAM assays were performed. For both urine LAM assays, frozen aliquots of unprocessed urine were 
thawed to ambient temperature and mixed manually. Samples that were not immediately used for 
testing were stored at 4°C for a maximum of four hours. FujiLAM tests were performed and graded 
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by trained study staff according to manufacturer recommendations. The detailed protocol and 
procedure for the FujiLAM test have been previously described.13 In brief, around 200 µl of urine was 
added to a reagent tube, mixed, and incubated for 40 minutes at room temperature. Following this, 
two drops of the urine were added to the sample port of the cartridge labelled one, and button two was 
pressed immediately. After observing a colour change to orange in the Go Next port, button three was 
pressed, and the result was read after the black control band appeared. The cartridge was visually 
inspected and interpreted by two independent staff who were blinded to other results from reference 
standard tests, comparator tests and to the index test results from each other. In case of discordant 
results, the two readers agreed upon a consensus result, and the final call was used for the analysis of 
primary endpoints. In the case of assay failure, the test was repeated once, and the repeat result used 
in the final analysis if successful. 
AlereLAM tests were performed according to manufacturer recommendations.17 The steps followed 
involved adding 60 µl of urine to the sample pad and reading off after 25 minutes using the 
manufacturer’s reference scale card.13 Identical to the FujiLAM reading, the AlereLAM was also 
interpreted by two independent and blinded staff. In the case of discordant AlereLAM results, the two 
readers agreed upon a consensus result, and the final call was used for the analysis of primary 
endpoints.  
The FujiLAM and AlereLAM testing were performed in parallel in batches of ten urine samples. 
After testing, laboratory staff took turns to record their independent interpretation of the AlereLAM 
for the entire batch followed by FujiLAM. Both LAM assays were interpreted by the same laboratory 
staff who recorded their interpretation of each test on a separate report form blinded to their own 
comparator test results for the same sample. We excluded urine samples from further analysis where 
at least one valid microbiological test for Mtb (either Xpert or culture) from the subject was not 
available. All available urine samples from the study cohort were tested with both tests. 
Statistical analysis 
Due to the secondary nature of the study, there was no formal sample size calculation. A convenience 
sample of all consecutively enrolled children was included in the primary and secondary analyses. In 
the primary analysis, using a microbiological reference standard, participants categorised as 
Confirmed TB were considered reference standard positive and participants with Unconfirmed TB 
and Unlikely TB as negative. In a composite reference standard, participants with Unconfirmed TB 
were reclassified as positive. We determined point estimates for sensitivity and specificity with 95% 
confidence interval (CI) of AlereLAM and FujiLAM against both a microbiological and composite 
reference standard for the entire cohort. In the secondary analysis, sensitivity and specificity of 
AlereLAM and FujiLAM were determined for predefined subgroups as follows: age below five years 
old vs five years and above; children living with HIV vs children that are HIV-negative; study country 
(Gambia, Mali, Nigeria or Tanzania); normal height vs stunted; and normal weight vs underweight.. 
Samples from all enrolled subjects were included in the secondary analysis. We estimated the pooled 
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sensitivity, specificity, and 95% CI using the Bayesian bivariate random-effects meta-analysis to 
account for the possible effects of heterogeneity across the subgroups. For the per country analysis, 
we estimated the 95% CI using the exact method. The results of the urine LAM assays were not 
included in the composite reference standard to avoid incorporation bias. All data were entered into 
Microsoft Excel and analysed using R (version 3.5.1). 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report. The sponsor of the study, FIND, is taking legal responsibility for the overall 
conduct of the study. This is a sponsor-investigator study, and as such FIND was involved in many 
aspects of the study including the protocol, controlling and training on the products under 
investigation, analysis plans and analysis. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
Results 
Of the 464 eligible children who were enrolled, 49 children were excluded from the main analysis 
because of the absence of a complete microbiological reference standard (n=12), urine samples not 
being available (n=36) and an invalid FujiLAM test (n=1) after repeat (Figure 1). Overall, urine 
samples from 415 children were included in the main analysis (167 from The Gambia, 67 from Mali, 
81 from Nigeria and 100 from Tanzania). A total of 63 (15%) were classified as Confirmed TB, 113 
(27%) as Unconfirmed TB, and 239 (58%) as Unlikely TB (Table 2).   
Using the microbiological reference standard, the pooled sensitivity of FujiLAM was 64·9% (95% CI 
43·7-85·2; 40 of 63) and 30.7% (8·6-61·6; 19 of 63) for AlereLAM (difference 34·2%; Figure 2). 
FujiLAM sensitivity was higher in the HIV-negative group (67·5% [41·8-88·0]) than children with 
HIV (54·8% [28·7-81·5]). Conversely, the sensitivity of AlereLAM was higher in children with HIV 
(36·6%, [13·8-70·4]) compared to the HIV negative group (26·6%, [1·2-66·4]), although, with wide 
and overlapping confidence intervals. In the analysis by age-group, FujiLAM showed higher 
sensitivity (61·8% [36·6-85·5] than AlereLAM (38·8% [0·4-98·9]; difference 23·0%) in children 
below five years of age, even though the confidence intervals were wide and overlapping. The 
difference in sensitivity between the assays was higher in patients aged five years and older. FujiLAM 
had a five-fold higher sensitivity than AlereLAM in the Gambia subgroup (50·0% [18·7-81·3] for 
FujiLAM vs 10·0% [0·3-44·5] for AlereLAM; difference 40·0%), a three-fold higher sensitivity in the 
Tanzania subgroup (70·6% [44·0-89·7] for FujiLAM vs 23·5% [6·8-49·9] for AlereLAM; difference 
47·1%), and a two-fold higher sensitivity in the Mali subgroup (56·5% [34·5-76·8] for FujiLAM vs 
26·1% [10·2-48·4] for AlereLAM), albeit with wide and overlapping confidence intervals. Both 
assays had higher point estimates for sensitivity in the Nigeria subgroup. The sensitivity for FujiLAM 




There was an overall lower sensitivity of both assays with the composite reference standard compared 
to the microbiological reference standard (32·9% [24·6-41·9] for FujiLAM vs 20·2% [12·3-29·4] for 
AlereLAM; difference 12·7%), although with similarly overlapping confidence intervals. However, 
the sensitivity for FujiLAM remained higher than for AlereLAM in all subgroup analyses (Figure 2, 
Appendix, page 4). Of note, the confidence intervals of the comparisons between FujiLAM and 
AlereLAM were wide and overlapping in all subgroup analyses except in children with normal height. 
Compared to the microbiological reference standard, there was a pooled specificity of 83·8% (76·5-
89·4) for FujiLAM and 87·8% (79·0-93·7) for AlereLAM, with a difference of -4·0% and 
overlapping confidence intervals. Overall specificity dropped with the composite reference standard 
to 83·3% (70·3-93·4) for FujiLAM and increased to 90·0% (81·6-95·6) for AlereLAM, with a larger 
difference (-6·7%) but again overlapping and wide confidence intervals. The specificity for 
AlereLAM remained higher than for FujiLAM in all subgroup analyses except the Mali and Tanzania 
cohorts (Figure 2 and Appendix, page 4). 
Discussion 
In this report, we compared the performance of two urine LAM point-of-care tests in over 400 urine 
samples from children with presumed PTB, including children with HIV, originating from four 
different African countries. The sensitivity of FujiLAM was more than double that of the AlereLAM 
test when evaluated against a microbiological reference. FujiLAM also had higher point estimates of 
sensitivity than AlereLAM in all sub-group analyses, while maintaining comparable specificity. Both 
assays performed better when the microbiological reference standard was used as opposed to the 
composite reference standard. However, both FujiLAM and AlereLAM assays had an overall 
suboptimal sensitivity when compared with the WHO target product profile’s minimum 
recommended sensitivity of ≥90% for a triage test or ≥66% for a diagnostic test.8 
Although the point estimates of the sensitivity for FujiLAM were higher than for AlereLAM in the 
entire cohort and all sub-group analyses, the confidence intervals were wide and overlapping in most 
of our comparisons. The sample size in our study was small for sensitivity calculation resulting in the 
wide confidence intervals. This explains the overlapping confidence intervals despite the observed 
difference in point estimates.  
There are few reports on the use of point-of-care LAM tests for TB diagnosis in children, none of 
which used FujiLAM. A previous study11 reported a pooled sensitivity of 48·3% (33·7–59·2) for 
AlereLAM, which is not very different from that observed in our study. Like our study, their tests 
were conducted on frozen, bio-banked urine samples collected from children below 15 years with 
symptoms suggestive of PTB. Conversely, Gautam and colleagues reported a higher sensitivity of 
73·2% for AlereLAM among children, of which 25·3% had microbiological confirmation for M. 
tuberculosis.18 The sensitivity of a test may often vary with factors that influence the pre-test 
probability of disease.19 These differences, such as the greater proportion of children above five years 
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old in their study (72% vs 53% in our study), make the results less comparable, and may explain the 
differences observed.   
In our study, the point estimates of FujiLAM sensitivity ranged from as low as 25·6% in the Gambia 
cohort (with the composite reference standard) to as high as 90·9% (with the X-pert-only 
microbiological reference standard) in the Nigeria cohort. While the results vary widely, the 
consistently better performance for FujiLAM compared to AlereLAM suggests that the design of 
FujiLAM enables improved detection of urinary LAM. This is consistent with the findings reported in 
adults with HIV.13,20 
It is interesting to note that the best performance of both assays was seen with the Nigerian samples, 
where the sensitivity was relatively higher compared to the other three countries. However, as Xpert 
Ultra alone was used as the reference standard in Nigeria, the patients identified as Confirmed TB in 
the Nigerian cohort were likely to be less paucibacillary than the patients in the other three cohorts 
where culture results had been available. As it is well established that the sensitivity of culture is 
higher than that of Xpert Ultra in children,21,22 the use of Xpert Ultra alone as a reference standard 
would, therefore, have been biased towards children with higher bacillary loads in order to be 
detectable by Xpert Ultra. As a consequence, the urine samples from Xpert-positive children might 
contain a higher amount of LAM, and therefore FujiLAM (and AlereLAM) would have potentially 
diagnosed more cases amongst the Nigerian cohort. This could explain the inflated sensitivity 
estimates seen with the Nigerian samples. The Nigerian children also had a higher rate of stunting, 
possibly an indication that they were overall sicker patients. However, we cannot currently verify 
these hypotheses, and this study was designed to conduct side-by-side comparisons of two available 
LAM tests rather than evaluate the performance of these tests in clinical subgroups.  
We observed a wide variation in the sensitivity of FujiLAM between the other three countries’ 
cohorts. While we used the same inclusion criteria and clinical recruitment procedures at all the study 
sites, the variation in sensitivity could reflect the fact that our study sites in the four countries 
represent different health care levels including community-based recruitment setting in The Gambia, 
urban comprehensive health care facility in Tanzania, to tertiary hospital-based recruitment setting in 
Mali and Nigeria. This is supported by the differences in the proportions of TB disease in each 
cohort.19 
We found that FujiLAM performed worse among the children with HIV than in the HIV negative 
group in our study, a finding that differs from results in adults.13,20 Given the relatively small numbers 
of children with HIV in the entire cohort, and even smaller numbers in the subgroup analyses, we are 
reluctant to draw any firm conclusions on the performance in the context of HIV. The observed 
performance in children living with HIV could have been due to chance.  
Even though the point estimates of FujiLAM specificity were lower than those for AlereLAM in most 
of the subgroup analyses, the differences in specificity were not significant. Also, FujiLAM had a 
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higher specificity than AlereLAM in the Mali and Tanzania cohorts. Based on analytical sensitivity 
studies23, particularly in respect to rapid growing non-tuberculous mycobacteria, one would expect a 
higher specificity clinically as well for FujiLAM. This is not in line with our observations. Overall, 
specificity was lower than observed in adult patients,13,20 which could have resulted from the higher 
amount of expected contamination from perineal flora in the process of urine collection in children 
versus adults.  
The tests were performed on bio-banked urine specimens in a research laboratory setting. Connelly 
and colleagues24 have suggested that fresh urine samples contain more detectable LAM than frozen 
samples, thus implying that the sensitivity of LAM-based tests would be improved with fresh 
samples. However, this finding has not been confirmed in studies using the FujiLAM test25 and 
accordingly, we would not expect any significant change in the sensitivity between fresh and frozen 
samples. 
The inclusion of urine samples of children from four different countries who were recruited using the 
same criteria is a strength of this study, as it allowed us to assess the performance of FujiLAM across 
different geographical settings. Additionally, the use of two reference standards further strengthens 
the study. Nevertheless, the heterogeneity of these cohorts, together with the difference in reference 
standard used in Nigeria, also represents one of its limitations.  
Despite the sizeable number and the geographical spread of our cohort, we believe that it is premature 
to conclude on the ultimate utility of FujiLAM in clinical practice based on these results alone. The 
potential clinical value of this test could be seen in children from whom adequate sputum cannot be 
obtained, and who would not otherwise be diagnosed. As it uses a very small quantity of easily 
obtainable urine, it avoids invasive procedures at an acceptable opportunity cost. Its high specificity 
qualifies it as a rule-in test that could guide further diagnostic evaluation. We, therefore, recommend 
larger and appropriately designed studies to evaluate the potential utility of FujiLAM and to 
demonstrate its added value in terms of showing how many additional TB cases, which would 
otherwise have been missed, will be detected if LAM is combined with Xpert and culture. 
In conclusion, FujiLAM showed substantially higher sensitivity than AlereLAM while maintaining 
comparable specificity. In the absence of the “dream test” advocated for by the WHO, FujiLAM has 
the potential to add value to the diagnosis of childhood TB. 
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Table and Figure titles and legend 
Figure 1: Study flow diagram 
Note: LAM = lipoarabinomannan; Ultra = Xpert MTB/RIF Ultra assay; FujiLAM = Fujifilm 
SILVAMP TB LAM assay; MRS = microbiological reference standard; CRS = composite reference 
standard 
 
Table 1: Revised classification of intrathoracic TB case definitions for diagnostic evaluation 
studies in children* 
*All children were followed up for a period of at least six months 
Note: TB = tuberculosis; Mtb = Mycobacterium tuberculosis  
 
Table 2: Demographic and clinical characteristics of study participants 
Note: IQR = inter-quartile range; TB = tuberculosis; HIV = human immunodeficiency virus 
 
Figure 2: Sensitivity, specificity and differences in sensitivity and specificity between FujiLAM and 
AlereLAM against the microbiological reference standard (MRS) and composite reference standard 
(CRS) 
Note: TP = true positive; FP = false negative; FN = false positive; TN = true negative; ΔSn = 
difference in sensitivity; ΔSp = difference in specificity 
 
Appendix Table and Figure titles and legend 
Supplementary Table 1: Supplementary Table 1: Study population, setting and location 
 
Supplementary Table 2: Reference standard outcomes among diagnostic categories  
* Note: NA = not applicable; FujiLAM = Fujifilm SILVAMP TB LAM assay; AlereLAM = Alere 
Determine LAM; Xpert Ultra = Xpert MTB/RIF Ultra assay 
 
Supplementary Figure 1: Sensitivity, specificity and differences in sensitivity and specificity 
between FujiLAM and AlereLAM against the microbiological reference standard (MRS) and 
composite reference standard (CRS) in different anthropometric groups 
Note: TP = true positive; FP = false negative; FN = false positive; TN = true negative; ΔSn = 












                          
  MRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
Overall 
FujiLAM 415 40 55 23 297 64·9% [43·7 – 85·2] 83·8% [76·5 – 89·4]   
  AlereLAM 415 19 40 44 312 30·7% [8·6 – 61·6] 87·8% [79·0 – 93·7]   
  ΔSn and ΔSp            34·2%  -4·0%    
  CRS             
  
Overall 
FujiLAM 415 58 37 118 202 32·9% [24·6 – 41·9] 83·3% [71·8 – 91·7]   
  AlereLAM 415 36 23 140 216 20·2% [12·3 – 29·4] 90·0% [81·6 – 95·6]   
  ΔSn and ΔSp            12·7%  -6·7%    
                                       
                          
  MRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
All HIV+ 
FujiLAM 61 8 11 7 35 54·8% [28·7 – 81·5] 75·9% [61·8 – 86·9]   
  AlereLAM 61 5 9 10 37 36·6% [13·8 – 70·4] 80·4% [66·3 – 91·0]   
  ΔSn and ΔSp            18·2%  -4·5%    
               
  
All HIV- 
FujiLAM 344 31 40 15 258 67·5% [41·8 – 88·0] 85·9% [79·2 – 91·0]   
  AlereLAM 344 14 30 32 268 26·6% [1·2 – 66·4] 89·1% [80·7 – 94·7]   
  ΔSn and ΔSp            40·9%  -3·2%    
               
  CRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
All HIV+ 
FujiLAM 61 14 5 30 12 31·9% [18·9 – 47·0] 71·4% [46·8 – 91·5]   
  AlereLAM 61 13 1 31 16 29·3% [16·3 – 44·6] 92·8% [72·6 – 99·8]   
  ΔSn and ΔSp            2·6%  -21·4%    
               
  
All HIV- 
FujiLAM 344 43 28 86 187 33·2% [23·7 – 43·5] 85·7% [76·2 – 92·2]   
  AlereLAM 344 23 21 106 194 15·3% [1·7 – 37·5] 89·3% [81·0 – 94·7]   
  ΔSn and ΔSp            17·9%  -3·6%    
                                       
                          
  MRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
Age <5 years 
FujiLAM 194 16 35 10 133 61·8% [36·6 – 85·5] 78·5% [69·1 – 86·0]   
  AlereLAM 194 9 32 17 136 38·8% [0·4 – 98·9] 80·5% [68·3 – 89·4]   
  ΔSn and ΔSp            23·0%  -2·0%    
               
  
Age >=5 years 
FujiLAM 221 24 20 13 164 67·1% [40·1 – 90·2] 88·8% [82·1 – 93·6]   
  AlereLAM 221 10 8 27 176 26·9% [7·2 – 54·8] 95·2% [89·7 – 98·3]   
  ΔSn and ΔSp            40·2%  -6·4%    
               
  CRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
Age <5 years 
FujiLAM 194 28 23 55 88 33·3% [19·8 – 48·3] 78·4% [66·5 – 87·2]   
  AlereLAM 194 20 21 63 90 23·3% [10·0 – 39·9] 81·4% [70·4 – 90·4]   
  ΔSn and ΔSp            10·0%  -3·0%    
               
  
Age >=5 years 
FujiLAM 221 30 14 63 114 32·7% [22·4 – 44·4] 88·2% [76·0 – 96·4]   
  AlereLAM 221 16 2 77 126 17·3% [9·6 – 27·4] 98·1% [93·7 – 99·9]   
  ΔSn and ΔSp            15·4%  -9·9%    
                                       
                          
  MRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
Gambia 
FujiLAM 167 5 19 5 138 50·0% [18·7 – 81·3] 87·9% [81·8 – 92·6]   
  AlereLAM 167 1 10 9 147 10·0% [0·3 – 44·5] 93·6% [88·6 – 96·9]   
  ΔSn and ΔSp            40·0%  -5·7%    
               
  
Mali 
FujiLAM 67 13 8 10 36 56·5% [34·5 – 76·8] 81·8% [67·3 – 91·8]   
  AlereLAM 67 6 9 17 35 26·1% [10·2 – 48·4] 79·5% [64·7 – 90·2]   
  ΔSn and ΔSp            30·4%  2·3%    
               
  
Nigeria 
FujiLAM 81 10 18 1 52 90·9% [58·7 – 99·8] 74·3% [62·4 – 84·0]   
  AlereLAM 81 8 6 3 64 72·7% [39·0 – 94·0] 91·4% [82·3 – 96·8]   
  ΔSn and ΔSp            18·2%  -17·1%    
               
  
Tanzania 
FujiLAM 100 12 10 5 73 70·6% [44·0 – 89·7] 88·0% [79·0 – 94·1]   
  AlereLAM 100 4 15 13 68 23·5% [6·8 – 49·9] 81·9% [72·0 – 89·5]   
  ΔSn and ΔSp            47·1%   6·0%     
               
  CRS Test N TP FP FN TN Sensitivity [95% CI] Specificity [95% CI]   
  
Gambia 
FujiLAM 167 11 13 32 111 25·6% [13·5 – 41·2] 89·5% [82·7 – 94·3]   
  AlereLAM 167 4 7 39 117 9·3% [2·6 – 22·1] 94·4% [88·7 – 97·7]   
  ΔSn and ΔSp            16·3%  -4·8%    
               
  
Mali 
FujiLAM 67 20 1 37 9 35·1% [22·9 – 48·9] 90·0% [55·5 – 99·8]   
  AlereLAM 67 14 1 43 9 24·6% [14·1 – 37·8] 90·0% [55·5 – 99·8]   
  ΔSn and ΔSp            10·5%  0·0%    
               
  
Nigeria 
FujiLAM 81 15 13 25 28 37·5% [22·7 – 54·2] 68·3% [51·9 – 81·9]   
  AlereLAM 81 11 3 29 38 27·5% [14·6 – 43·9] 92·7% [80·1 – 98·5]   
  ΔSn and ΔSp            10·0%  -24·4%    
               
  
Tanzania 
FujiLAM 100 12 10 24 54 33·3% [18·6 – 51·0] 84·4% [73·1 – 92·2]   
  AlereLAM 100 7 12 29 52 19·4% [8·2 – 36·0] 81·3% [69·5 – 89·9]   
  ΔSn and ΔSp            13·9%  3·1%    
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Table 1: Revised classification of intrathoracic TB case definitions for diagnostic evaluation studies in children* 
Case definition Criteria 
Confirmed TB Bacteriological confirmation of Mtb (culture and/or Xpert MTB/RIF assay) from at least 1 respiratory specimen 
Unconfirmed TB Bacteriological confirmation NOT obtained AND at least 2 of the following: 
 
• Symptoms/signs suggestive of tuberculosis  
 
• Chest radiograph consistent with tuberculosis 
 
• Close tuberculosis exposure 
  • Positive response to tuberculosis treatment (requires documented positive clinical response to TB treatment—no time duration specified) 
Unlikely TB Bacteriological confirmation NOT obtained AND Criteria for “unconfirmed tuberculosis” NOT met  
 




Table 2: Demographic and clinical characteristics of study participants 
  Gambia Mali Nigeria Tanzania All Patients 
Variable (N=167)   (N=67)   (N=81)   (N=100)   (N=415)   
Median age - years (IQR) 5.6 [2.3;9.3] 6 [2.6;11.0] 4.9 [1.7;8.9] 5.4 [2.3;8.8] 5.6 [2.3;9.3] 
Age <5 years (%) 67 40.1 28 41.8 43 53.1 56 56.0 194 46.7 
Age >5 years (%) 100 59.9 39 58.2 38 46.9 44 44.0 221 53.3 
Males - no. (%) 98 58.7 44 65.7 30 37.0 53 53.0 225 54.2 
           
Distribution in diagnostic categories                     
Confirmed TB - no. (%) 12 7.2 23 34.3 11 13.6 17 17.0 63 15.2 
Unconfirmed TB - no. (%) 31 18.6 34 50.7 29 35.8 19 19.0 113 27.2 
Unlikely TB - no. (%) 124 74.3 10 14.9 41 50.6 64 64.0 239 57.6 
           
HIV status                     
Positive (%) 15 9.0 21 31.3 8 9.9 17 17.0 61 14.7 
Negative (%) 148 88.6 46 68.7 68 84.0 82 82.0 344 82.9 
Unknown (%) 4 2.4 0 0.0 5 6.2 1 1.0 10 2.4 
           
Anthropometry                     
Underweight (%) 74 44.3 40 59.7 36 44.4 31 31.0 181 43.6 
Stunted (%) 34 20.4 17 25.4 45 55.6 38 38.0 134 32.3 
 
